Risk factors for thrombotic events in Philadelphia chromosome-negative myeloproliferative neoplasms: a retrospective analysis of 336 cases
Thrombotic events are one of the main factors affecting the survival of patients with Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs). Therefore, a comprehensive understanding of the early relevant high-risk factors makes sense for early prevention and reducing mortality in these patients. In this study, we conducted a retrospective analysis of 336 patients with Ph- MPN and summarized the clinical characteristics, incidence of thrombotic events and influencing factors. Thrombotic events occurred in 27.7% (93/336) of patients. Among the thrombotic events, arterial thrombosis occurred in 86 cases (92.5%), the most common thrombotic event was cerebral infarction (69/93, 74.2%). Univariate analysis and logistic regression identified that diagnosis of Polycythemia Vera (PV)/Essential Thrombocythemia (ET), thrombotic events before diagnosis and D-dimer≥1mg/L were the independent risk factors for thrombotic events at initial diagnosis in MPN patients (<i>P</i><0.05). Receiver operating characteristic (ROC) curve analysis revealed that the integrated predictive efficacy of the triple-variable combination was markedly superior to that of any single parameter alone, yielding a sensitivity of 72.04% (95% CI: 61.8%-80.9%), a specificity of 74.49% (95% CI: 68.5%-79.8%), and an area under the curve (AUC) of 0.771 (95% CI: 0.723 - 0.815). Additionally, univariate analysis further identified smoking history, elevated hemoglobin (Hb≥136g/L), hematocrit (HCT≥0.42), D-dimer-to-fibrinogen ratio (DFR≥0.243) and JAK2<sup>V617F</sup> mutation as potential risk factors for thrombosis (<i>P</i><0.05), necessitating validation in future studies. These findings facilitate the early identification of Ph-MPN patients at heightened risk for thrombotic events, enabling the implementation of targeted prophylactic strategies to mitigate thrombotic risk.
Authors
- Lingxiu Zhang (ORCID: https://orcid.org/0000-0003-0232-4001)
- Xiufeng Wang (ORCID: https://orcid.org/0000-0003-3629-1738)
- Yuan Zhang (ORCID: https://orcid.org/0000-0002-4174-0641)
- Wu Sun (ORCID: https://orcid.org/0009-0007-0206-7881)
- Yan Huang (ORCID: https://orcid.org/0000-0002-4331-0581)
- Guoqing Lv (ORCID: https://orcid.org/0000-0002-9591-1098)
- Yan Guo
- Youmei Zi
- Man Yang
Institutions
- First Affiliated Hospital of Xinxiang Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.3389/fonc.2025.1639250
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Science and Technology Department of Henan Province